CAMBRIDGE, Mass.--(BUSINESS WIRE)--IntegraGen (www.integragen.com) a biotechnology company dedicated to gene discovery and the development of molecular diagnostic products and services, announced today the results of a study which reports the ability to better predict the risk of autism in children who have an older sibling diagnosed with an autism spectrum disorder (ASD). The study, presented during the Society for Developmental and Behavioral Pediatrics meeting in San Antonio, Texas, is based on a test which identifies genetic variants which the company’s researchers showed to be associated with autism. Over 1,200 families and nearly 2,000 children were included in the study.
